Fritextsökning
Artiklar per år
Innehållstyper
-
He saved lives with his theories – was ostracised and ended up in a mental hospital
Hungarian doctor Ignaz Semmelweis (1818-1865) undoubtedly possessed plenty of persistence, diligence and sound reasoning skills – but he was hardly blessed with luck and timing.
-
Ny rapport – forskning ges inte rätt förutsättningar
En ny rapport från Cancerfonden tyder på att klinisk forskning i Sverige inte följs upp tillräckligt eller får rätt förutsättningar från politiker.
-
"Unclear proposal from the EU Commission on how to solve the MDR challenges"
Even before the EU regulation on medical devices (MDR) came into force, medical technology companies and doctors were concerned that it would endanger the availability of medical devices in the EU. Unfortunately, the fears have come true.
-
The new Astra Zeneca CEO: “An incredibly exciting phase”
Almost 27 years have passed since Per Alfredsson from Södertälje stepped into Astra Zeneca as a newly hired engineer. After countless different roles, including heading the production of the company’s Covid vaccine, he is now advancing to the absolute top.
-
Sweden is organising a large life science conference as part of the EU presidency
On 26-27 June, Sweden will host a European meeting on life science.
-
“Everyone is screaming for talent”
Attracting talent is one of the life science industry’s major future challenges, which was one of the conclusions of the panel discussion that ended the New Horizons in Biologics & Bioprocessing conference on 15 December.
-
Missnöjd med din julklappsslips? Här är våra läsetips
-
Cancerbolaget Anocca får EU-lån på 25 miljoner euro
Södertäljebaserade Anocca har säkrat ett lån på 25 miljoner euro från Europeiska investeringsbanken (EIB) för fortsatt utveckling av sina skräddarsydda cancerbehandlingar. Dessutom uppges företaget planera en finansieringsrunda modell större.
-
”Alla skriker efter talang”
Att locka till sig begåvningarna är en av life science-branschens stora framtidsutmaningar. Det var en av slutsatserna i det panelsamtal som avslutade konferensen New Horizons in Biologics & Bioprocessing på torsdagen.
-
Svenskt DNA-vaccin i fokus — "Villigheten att dela data och kompetens har varit en nyckel"
Utvecklingen av ett svenskt DNA-baserat covidvaccin som ska ge bredare immunitet mot sars-cov-2-virusets olika varianter och mutationer är på väg in i klinisk fas. Projektet och dess utveckling beskrevs i en presentation på eventet New Horizons på
-
ALS – When the body has given up, but the brain persists
The nerve disease ALS gradually deprives the patient of control over the muscles and, eventually, also of speech. The eyes continue to function, though, and with the help of, among other things, a Swedish-developed invention, communication with the outside world can continue. “It’s their window to the world,” says ALS researcher Caroline Ingre.
-
“Photon counting in computed tomography is the holy grail”
Erik Fredenberg, a researcher in physics at KTH and GE, is working to implement photon-counting CT in clinics. To shorten lead times and reduce the radiation dose in patients, he is setting out to develop a framework for virtual clinical trials
-
Great Swedish innovations: Eye treatment became a feather in Pharmacia’s cap
From complicated and sometimes risky surgery to a routine procedure. Pharmacia’s injectable Healon revolutionised the field of eye surgery - and is considered by us one of the most important contemporary Swedish innovations in the field of medicine.
-
New study: Post-Covid symptoms are common even after mild Covid-19
According to researchers at the University of Gothenburg, loss of smell and taste, shortness of breath and chest symptoms are the most common complaints after a mild Covid infection.
-
Ny ordförande för Atlas Antibodies
Åsa Riisberg, styrelseproffs och tidigare partner i EQT, tar över ordförandeklubban i Atlas Antibodies.
-
Christoffer Rosenblad blir permanent vd på Xvivo
Transplantationsbolaget Xvivo Perfusion har utsett Christoffer Rosenblad till vd med omedelbar verkan. Han har haft rollen som tillförordnad vd sedan slutet av september.
-
She creates pharmaceuticals on a 3D printer
The correct dosage for each individual, regardless of whether the pharmaceutical is for a seriously ill child or a frail elderly person, is the mission of a well-advanced project with 3D-printed drugs at Uppsala University. “It will soon be available in clinics”, says Christel Bergström, who is heading the project.
-
The stomach medication that became the biggest blockbuster of the 1990s
The omeprazole molecule was synthesised as early as 1979, but it took many years before the then Astra had an approved pharmaceutical. Once this happened, a tablet was available that was soon to help millions of people worldwide and break all sales records.
-
The most important Swedish medical innovations: Our ranking
Life Science Sweden turns 20 years old – and celebrates by producing a top list of the 20 most important contemporary Swedish innovations in the field of medicine.
-
“We are Europe’s hotspot in life science”
The Medicon Valley Alliance has worked for competence development in life science in Denmark and Sweden for a quarter of a century. Anette Steenberg, CEO, sees the anniversary as a recognition of MVA’s explosive power.
-
Magmedicinen som blev 90-talets största blockbuster
Redan 1979 syntetiserades omeprazolmolekylen. Men det kom att dröja många år innan dåvarande Astra hade ett godkänt läkemedel. När det väl skedde fanns en tablett som kom att hjälpa miljontals människor i världen – och slå alla försäljningsrekord.
-
Medtech-bolag ställer om – patienter som vilken konsument som helst
Patienter hanterar sin hälsa på samma sätt som de bokar resor eller nätshoppar, enligt en ny rapport. Nu lägger flera medtech-bolag om sin strategi.
-
Targinta skjuter på börsnotering: "Svåra marknadsförhållanden"
Targinta har beslutat att skjuta upp sina planer på börsnotering och fokuserar på en klinisk fas 0-studie, en mikrodoseringsstudie, för bolagets antikroppar i cancerpatienter.
-
Spermosens vd slutar
Medicinteknikbolaget Spermosens vd John Lempert har beslutat sig för att avgå.